Clinical Trial Update: Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating apremilast 30 mg twice daily in combination with narrowband UVB for plaque psoriasis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• OTEZLA (apremilast)

Snippet

Sponsor: Psoriasis Treatment Center of Central New Jersey | Conditions: Plaque Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2019-01-28